Secondary biomarker analysis of GEICAM/9906 (567 HR+/HER2− node-positive tumours): with a low SETER/PR index (16.2%), adding weekly paclitaxel to FEC improved distant recurrence-free interval (HR 0.46); no benefit at ≥0.75 (HR 1.02). OS and BCSS not significant.
RCTn = 567
Martín et al. Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor-Positive Breast Cancer in the GEICAM/9906 Trial